Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Status of Claims
Claims 1-10 and 12-15 are currently pending as of the response and amendments filed on 3/6/26. Claim 11 was previously canceled.
The amendments to the specification filed on 3/6/26 to correct typographical errors are acknowledged and accepted.
The rejection of claims 1, 4, and 8 under 35 USC 112(b) is withdrawn in view of the amendments to claim 1. However, despite the amendments to claim 1, claim 6 remains rejected under 35 USC 112(b), as discussed below.
Claims 1-10 and 12-15 were examined. Claims 1-5, 7-10, and 12-15 are allowed. Claim 6 is rejected.
Claim Rejections-35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claim 6 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Claim 6 depends indirectly from claim 1 and recites a number of compounds that lack antecedent basis from formula (I) in claim 1 (see below):
1-((1H-pyrazolo[3,4-b]pyridine-5-yl)methyl)-N-(3-fluoro-5-(trifluoromethyl)phenyl)indoline-6-carboxamide
PNG
media_image1.png
200
400
media_image1.png
Greyscale
. This compound lacks antecedent basis from amended claim 1, because while claim 1 allows R2 to include fluoro and CF3, only one group R2 is allowed. The other group attached to the phenyl ring, R3, doesn’t allow for fluoro or CF3.
Claim 6 also recites N-(3-fluoro-5-(trifluoromethyl)phenyl)-1-(imidazo[1,2-a]pyrazin-3-ylmethyl)indoline-6-carboxamide:
PNG
media_image2.png
200
400
media_image2.png
Greyscale
. This compound lacks antecedent basis from amended claim 1, because while claim 1 allows R2 to include fluoro and CF3, only one group R2 is allowed. The other group attached to the phenyl ring, R3, doesn’t allow for fluoro or CF3.
Claim 6 recites the compound N-(3-fluoro-5-(trifluoromethoxy)phenyl)-1-(imidazo[1,2-a]pyrazin-3-ylmethyl)indoline-6-carboxamide:
PNG
media_image3.png
200
400
media_image3.png
Greyscale
. This compound lacks antecedent basis from amended claim 1, because while claim 1 allows R2 to include fluoro and -OCF3, only one group R2 is allowed. The other group attached to the phenyl ring, R3, doesn’t allow for fluoro or -OCF3.
Claim 6 also recites the compound N-(3-fluoro-5-(trifluoromethoxy)phenyl)-1-(imidazo[1,2-a]pyridine-3-ylmethyl)indoline-6-carboxamide:
PNG
media_image4.png
200
400
media_image4.png
Greyscale
. This compound lacks antecedent basis from amended claim 1, because while claim 1 allows R2 to include fluoro and -OCF3, only one group R2 is allowed. The other group attached to the phenyl ring, R3, doesn’t allow for fluoro or -OCF3.
Claim 6 also recites the compound N-(3-fluoro-5-(trifluoromethyl)phenyl)-1-(imidazo[1,2-a]pyridine-3-ylmethyl)indoline-6-carboxamide:
PNG
media_image5.png
200
400
media_image5.png
Greyscale
. This compound lacks antecedent basis from amended claim 1, because while claim 1 allows R2 to include fluoro and CF3, only one group R2 is allowed. The other group attached to the phenyl ring, R3, doesn’t allow for fluoro or CF3.
Claim 6 recites the compound 1-((1H-benzo[d]imidazole-5-yl)methyl)-N-(3-fluoro-5-(trifluoromethyl)phenyl)indoline-6-carboxamide:
PNG
media_image6.png
200
400
media_image6.png
Greyscale
. This compound lacks antecedent basis from amended claim 1, because while claim 1 allows R2 to include fluoro and CF3, only one group R2 is allowed. The other group attached to the phenyl ring, R3, doesn’t allow for fluoro or CF3.
Information Disclosure Statement
The IDS filed on 2/9/26 has been considered.
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Correspondence
Any inquiry concerning this communication or earlier communications from the examiner should be directed to SARAH PIHONAK whose telephone number is (571)270-7710. The examiner can normally be reached Monday-Friday 9:00-5:30 EST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kortney Klinkel can be reached at 571-270-5239. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
SARAH . PIHONAK
Primary Examiner
Art Unit 1627
/SARAH PIHONAK/Primary Examiner, Art Unit 1627
Prosecution Insights